![](https://s3.amazonaws.com/cache.altmetric.com/policy/thumbnails/thumbnail-8752bb5cb6af8e9202d6ef8f251954cc45ccf4ae0de94b9ac72c5dcb3dda3cc7.jpg)
Tisagenlecleucel (Kymriah) for Pediatric Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma
Cited by Canadian Agency for Drugs and Technologies in Health on
CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.